Form 8-K Theravance Biopharma, For: Feb 27
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Theravance Biopharma (TBPH) Misses Q4 EPS by 31c
February 27, 2017 4:09 PM ESTTheravance Biopharma (NASDAQ: TBPH) reported Q4 EPS of ($1.36), $0.31 worse than the analyst estimate of ($1.05). Revenue for the quarter came in at $5.7 million versus the consensus estimate of $4.9 million.
Outlook
We expect to fund advancements across all stages of our development pipeline, including investment towards... More
